Pacira BioSciences, Inc. (PCRX)
- Sector
- Pharmaceuticals
- Last price
- $36.48
- As of
Kresmion compiles this page from PCRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Pacira BioSciences, Inc. (PCRX): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-17.
See the full PCRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PCRX on one page. Preview it with sample data, then open it live with a free account.
Preview the PCRX dossierActive events for PCRX
- high13F: large increase
CITADEL ADVISORS LLC added +1878% to PCRX (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +312% to PCRX (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 10.6%, EPS $0.73 vs $0.6603 estimate
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 53% of PCRX (2026Q1)
- mediumEarnings above estimates
Q3-2025: Beat consensus by 5.3% - EPS $0.7 vs $0.6649 estimate
FREE, NO ACCOUNT
Every event on PCRX, as it fires
You are seeing 5 of 6 events recorded on PCRX since 2026-06-02.
The five above landed across 4 days. The other 1 were recorded on those same days. 3 of the 6 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
PCRX positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 695127100 · 2026Q3 | $41.9M | 0.06% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PCRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on PCRX
- PCRX share buybacks Cash paid for repurchases, shares bought and program authorizations, from SEC filings.
- PCRX insider trading clusters Three or more insiders filing the same direction within 30 days, from SEC Form 4.
- PCRX against its peers Growth, margins and valuation beside the industry median, from annual SEC filings.
PCRX against its peers
PCRX's operating margin of 2.6% ranks in the 50th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | PCRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 726M USD | 411M USD | 68 | 19 |
| Gross margin | 79.4% | 66.3% | 77 | 10 |
| Operating margin | 2.6% | 5.0% | 50 | 18 |
| Net margin | 1.0% | 0.2% | 57 | 19 |
| Return on equity | 1.0% | -14.3% | 63 | 22 |
| P / E | 228.0x | 14.6x | 94 | 8 |
| 1 year | 49.9% | 4.6% | 74 | 24 |
Peers (25): NUVB, PAHC, GPCR, OCUL, INVA, ANIP, SUPN, NKTR, AMPH, OMER, ANRO, TRVI, HRMY, ESPR.D, COLL, ALMS, XERS, BHC, ACRS, OGN, TARS, AMLX, LQDA, AVIR, ACB. Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PCRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in PCRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on PCRX in the last 180 days.
Upstream: SEC EDGAR filings for PCRX
Kresmion, "Pacira BioSciences, Inc. (PCRX) institutional holdings and SEC filings", data as of 2026-11-17, https://kresmion.com/research/PCRX. Upstream data: SEC EDGAR filings for PCRX.
Link to this data (HTML):
<a href="https://kresmion.com/research/PCRX">Pacira BioSciences, Inc. (PCRX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow PCRX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to PCRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.